Table 7 Renal outcomes and prognostic indicators for patients with biopsy-proven HN in the present study and in previous reports

Takebayashi [21]

590

2.5:1

56.5

1.90(ND)

ND

154(SBP)

87(DBP)

10.1

49.2 % of 345 cases reached endpoint event (Scr ≥3 mg/dl)

Poor or no control of BP, global glomerulosclerosis (>40 %), presence of collapsed glomeruli and/or segmental glomerulosclerosis

Marcantoni [22]

62^a

1.3:1

58.7

3.40(ND)

1.8

105 ± 3(MAP)

1.9

47.8 % of 23 cases reached ESRD

ND

Wehrmann [13]

170

5.0:1

ND

ND

ND

ND

ND

5- and 10-year renal survival rates were 35.9 % and 23.6 %, respectively

Baseline Scr

Vikse [10]

102

2.0:1

55.4

1.87(ND)

0.4

156 ± 28(SBP);

92 ± 14(DBP)

11.7

5- and 10-year renal survival rates were 80 % and 72 %, respectively

Baseline Scr, proteinuria

Norris [11]

1094^a

1.6:1

54.6

ND(46.4)

0.3

150 ± 24(SBP);

96 ± 14(DBP)

3.9

13.1 % reached endpoint event (50 % or 25 ml/min per 1.73 m²decline in GFR or ESRD)

Baseline proteinuria, GFR, Scr,urea nitrogen, phosphorus

Dasgupta [12]

60

2.0:1

58.0

2.79(36.0)

2.3

179 ± 25(SBP);

105 ± 15(DBP)

6.7

5- and 10-year renal survival rates were 56 % and 35 %, respectively

Baseline Scr, mean SBP and DBP during follow-up (univariate analysis), DBP during follow-up (multivariate analysis)

Yu [39]

61

9.2:1

32.0

6.33(ND)

3.46

ND

2.5

45.9 % reached ESRD

ND

This study

194

4.7:1

43.8

1.61(49.6)

0.80

195 ± 37(SBP);

126 ± 26(DBP)

3.0

5- and 10-year renal survival rates were 84.5 and 48.9 %, respectively

Baseline eGFR, proteinuria, anemia, the percentage of global glomerulosclerosis and TAIF